C3J Therapeutics
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Technology
  • Pipeline
  • Publications
  • News
    • Press Releases
    • Bacteriophage
  • Events
  • Careers
  • Contact

Targeted Antimicrobials for Disease-Causing Pathogens

The overuse of broad-spectrum antibiotics has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Broad-spectrum antibiotics are also recognized to disrupt the ecology of the human microbiome leading to disease.

C3J Therapeutics is focused on improving human health through the development of novel targeted antimicrobials utilizing two proprietary platforms – synthetic bacteriophage and antimicrobial peptides.

LATEST NEWS: C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics

Home

  • C3J Therapeutics
  • Home
  • About Us
  • Technology
  • Pipeline
  • News
  • Contact

© 2018 C3J Therapeutics Custom web design by media junction®